|
2018 Book Chapter Chronic lung allograft dysfunction: phenotypes and the futureChambers, Daniel C. (2018). Chronic lung allograft dysfunction: phenotypes and the future. Essentials in lung transplantation. (pp. 119-129) edited by Allan R. Glanville. Cham, Switzerland: Springer International Publishing. doi: 10.1007/978-3-319-90933-2_11 |
|
2015 Book Chapter Mesenchymal stromal cell-based therapies for lung diseaseChambers, Daniel (2015). Mesenchymal stromal cell-based therapies for lung disease. Stem Cells in the Lung: Development, Repair and Regeneration. (pp. 225-242) edited by Ivan Bertoncello. Heidelberg, Germany: Springer Spektrum. doi: 10.1007/978-3-319-21082-7_14 |
|
2012 Book Chapter Pulmonary clinical applications for mesenchymal stem cellsChambers, D. and Hopkins, P. (2012). Pulmonary clinical applications for mesenchymal stem cells. Mesenchymal stem cell therapy. (pp. 87-99) edited by Lucas G. Chase and Mohan C. Vemuri. Totowa, NJ USA: Humana Press. doi: 10.1007/978-1-62703-200-1_5 |
|
2011 Book Chapter Mold infections in cardiothoracic transplantationChambers, Daniel C. and Sole, Amparo (2011). Mold infections in cardiothoracic transplantation. Diagnosis and Management of Infectious Diseases in Cardiothoracic Transplantation and Mechanical Circulatory Support. (pp. 195-209) edited by Martha L. Mooney, Margaret M. Hannan, Shahid Husain and James K. Kirklin. Addison, TX, United States: International Society of Heart and Lung Transplantation. |
|
2009 Book Chapter Leucocyte intracellular cytokines in lung transplant patients : A more physiological indicator of immunosuppression than plasma drug levelsHodge, Greg, Hodge, S., reynolds, P., Chambers, D. and Holmes, M. (2009). Leucocyte intracellular cytokines in lung transplant patients : A more physiological indicator of immunosuppression than plasma drug levels. Immunosuppression : New research. (pp. 91-115) edited by Charles B. Taylor. New York, NY, United States: Nova Biomedical Books. |
